Top

World Journal of Surgery

Published in:

01-11-2012

Surgical Outcomes After Resection of Both Hepatic and Pulmonary Metastases From Colorectal Cancer

Authors: Yasuo Sakamoto, Yoshihisa Sakaguchi, Eiji Oki, Kazuhito Minami, Yasushi Toh, Takeshi Okamura

Published in: World Journal of Surgery | Issue 11/2012

Abstract

Background

The efficacy and the indications of resection of synchronous or metachronous hepatic and pulmonary metastases from colorectal cancer (CRC) are controversial. This study retrospectively reviewed the cases of CRC patients who underwent both liver and lung resection to define the appropriate indications for surgical resection in patients with hepatic and pulmonary metastases.

Methods

A total of 39 patients with both hepatic and pulmonary metastases from CRC underwent both liver and lung resection from January 1987 to December 2009. The relapse-free survival (RFS) and overall survival (OS) from the resection for the first metastasis were evaluated by a Kaplan–Meyer analysis. Prognostic factors were analyzed using the log-rank test and a Cox proportional hazards model.

Results

The median RFS and the 5-year RFS rate of all patients were 12 months and 2.6 %, respectively. The median survival time (MST) and 5-year OS rate of all patients were 66 months and 48.3 %, respectively. The MST of the patients with a long (>1 year) disease-free interval (DFI) could not be calculated, but their 5-year OS rate was 73.7 %. In contrast, the MST and 5-year OS rate of the patients with a short (<1 year) DFI were 29 months and 37.5 %, respectively. The short DFI was the only prognostic factor in the multivariate analysis.

Conclusions

Aggressive surgical resection of both hepatic and pulmonary metastases from CRC should be undertaken in selective patients, including those with a long DFI.

Fusai G, Davidson BR (2003) Management of colorectal liver metastases. Colorectal Dis 5:2–23PubMedCrossRef

Rougier P, Milan C, Lazorthes F et al (1995) Prospective study of prognostic factors in patients with unresected metastases from colorectal cancer. Br J Surg 82:1397–1400PubMedCrossRef

Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg 230:309–321PubMedCrossRef

Ohlsson B, Stenram U, Tranberg KG (1998) Resection of colorectal liver metastases: 25-year experience. World J Surg 22:268. doi:10.1002/14651858.CD002200 PubMedCrossRef

Jamison RL, Donohue JH, Nagorney DM et al (1997) Hepatic resection for metastatic cancer results in cure for some patients. Arch Surg 132:505–511PubMedCrossRef

Bradley AL, Chapman WC, Wright JK et al (1999) Surgical experience with hepatic colorectal metastasis. Am Surg 65:560–566PubMed

Abdalla EK, Vauthey JN, Ellis LM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825PubMedCrossRef

Goya T, Miyazawa N, Kondo H et al (1989) Surgical resection of pulmonary metastases from colorectal cancer: 10-year follow-up. Cancer 64:1418–1421PubMedCrossRef

Mansel JK, Zinsmeister AR, Pairolero PC et al (1986) Pulmonary resection of metastatic colorectal adenocarcinoma: a ten year experience. Chest 89:109–112PubMedCrossRef

10.

Inoue M, Ohta M, Iuchi K et al (2004) Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 78:238–244PubMedCrossRef

11.

McCormack PM, Burt ME, Bains MS et al (1992) Lung resection for colorectal metastases: 10 year results. Arch Surg 127:1406CrossRef

12.

Okumura S, Kondo H, Tsuboi M et al (1996) Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 112:867–874PubMedCrossRef

13.

Kobayashi K, Kawamura M, Ishihara T (1999) Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. J Thorac Cardiovasc Surg 118:1090–1096PubMedCrossRef

14.

Nagakura S, Shirai Y, Yamato Y et al (2001) Simultaneous detection of colorectal carcinoma liver and lung metastases does not warrant resection. J Am Coll Surg 193:153–160PubMedCrossRef

15.

Mineo TC, Ambrogi V, Tonini G et al (2003) Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma. J Am Coll Surg 197:386–391PubMedCrossRef

16.

Reddy RH, Kumar B, Shah R et al (2004) Staged pulmonary and hepatic metastasectomy in colorectal cancer: is it worth it? Eur J Cardiothorac Surg 25:151–154PubMedCrossRef

17.

Shah SA, Haddad R, Al-Sukhni W et al (2006) Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 202:468–475PubMedCrossRef

18.

Miller G, Biernacki P, Kemeny NE et al (2007) Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 205:231–238PubMedCrossRef

19.

Rena O, Casadio C, Viano F et al (2002) Pulmonary resection for metastases from colorectal cancer: factors influencing prognosis: twenty-year experience. Eur J Cardiothorac Surg 21:906–912PubMedCrossRef

20.

Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30PubMedCrossRef

21.

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRef

22.

Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019PubMedCrossRef

23.

Van Cutsem E, Köhne CH, Láng I et al (2011) KRAS cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019PubMedCrossRef

24.

Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671PubMedCrossRef

25.

Portier G, Elias D, Bouche O et al (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976–4982PubMedCrossRef

26.

Mitry E, Fields AL, Bleiberg H et al (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26:4906–4911PubMedCrossRef

27.

Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016PubMedCrossRef

Title: Surgical Outcomes After Resection of Both Hepatic and Pulmonary Metastases From Colorectal Cancer
Authors: Yasuo Sakamoto
Yoshihisa Sakaguchi
Eiji Oki
Kazuhito Minami
Yasushi Toh
Takeshi Okamura
Publication date: 01-11-2012
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 11/2012
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-012-1708-8

At a glance: The STEP trials

Springer Medicine

Surgical Outcomes After Resection of Both Hepatic and Pulmonary Metastases From Colorectal Cancer

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2012

Development of a Formula to Predict Parathyroid Carcinoma in Patients with Primary Hyperparathyroidism

Robotic versus Conventional Laparoscopic Surgery for Rectal Cancer: A Cost Analysis from A Single Institute in Korea

Survival Benefit of Palliative Gastrectomy in Gastric Cancer Patients with Peritoneal Metastasis

Routine Chest X-Ray Prior to Thyroid Surgery: Is It Always Necessary?

Defining the Optimal Cut-off Values and Research Methodology for Evaluating Systemic Inflammatory Markers in Clinical Outcome Prediction: Reply

Long-term Outcomes Following Aggressive Management of Recurrent Hepatocellular Carcinoma After Upfront Liver Resection